Unlocking the potential of epigenetics for early cancer detection and personalized health solutions.
cervical cancer, and monitor exposure to tobacco smoke.
MetaGen Mutations Multi-Test
MGMT gene testing serves as a crucial tool for physicians and surgeons in tailoring precise cancer treatment plans. This genetic test delves into the intricacies of the MGMT gene, a key player in the body's response to chemotherapy. By understanding the genetic characteristics related to this gene, physicians gain valuable insights into the patient's likelihood of responding to chemotherapy and can customize treatment strategies accordingly. MGMT gene testing stands at the forefront of personalized medicine, enabling healthcare professionals to make informed decisions about chemotherapy prescriptions based on the patient's unique genetic profile, ultimately optimizing the effectiveness of cancer treatment.
Did you know that it’s possible to detect your body’s true age? It is through this easy to take detection test. Stop counting your age by birthdays and start determining your age based on your DNA, lifestyle choices, and hidden genetic stories.
HKG epiTherapeutics is proud to introduce epiPsych, a pioneering saliva-based epigenetic test designed to uncover the genetic underpinnings of psychiatric conditions. This innovative approach offers a non-invasive pathway to gaining profound insights into the epigenetic factors influencing mental health.
MTL Epitherapeutics is proud to introduce epiPsych to the Canadian market, a pioneering saliva-based epigenetic test designed to uncover the genetic underpinnings of psychiatric conditions. This innovative approach offers Canadians a non-invasive pathway to gaining profound insights into the epigenetic factors influencing mental health.
Thanks to the development of our epiPancancer, we can detect up to 33 different types of cancer. Current biomarkers lack sensitivity and specificity to detect cancer early. Available biomarkers and diagnostic methods are invasive and cannot be used for follow-up of a healthy population. Our scientists conducted multiple cancer blood tests to investigate DNA methylation results from normal tissues, blood, and cancer from thousands of people and used proprietary methods to discover unique methylation profiles that are categorically different between each tissue type. Our new Binary Categorical Differentiation (BCD) method identifies stark differences between cancer cells and normal cells.
We are advancing our capabilities by incorporating human papillomavirus (HPV) testing in cervical biopsies. While Pap smear has traditionally focused on identifying abnormal cells in the cervix, our ongoing research extends its utility to include the detection of HPV, offering a more comprehensive assessment of cervical health.
This is a liquid biopsy for early detection of liver cancer that detects conversion of patients with chronic hepatitis or healthy controls to early-stage liver cancer HCC. This is a next-generation sequencing assay that is fully optimized and clinically tested. Targets were clinically validated in studies in Yuan Hospital in Beijing and published in Clinical Epigenetics 2018. epiLiver has PCT world patent protection in the U.S., Europe, Canada, Indonesia, India, and Japan.